Best Life Sciences Companies in Plymouth, United States
The 40 best Life Sciences companies in Plymouth, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: IDRx.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Plymouth
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IDRx Developer of precision combination therapies for cancer | $242M | 24 mo ago | Acquired | 19 | Nicholas Lydon Co-Founder | WordPress Block EditorWordPressMySQL+23 | 5 patents KIT inhibitor-based combination therapies for cancer treatment | — |
| 2 | Monteris Minimally invasive robotic laser thermotherapy 55Funding top 15%Moat top 31%Talent top 38%Market top 43% All 8 signals ▾Fundingtop 15% Moattop 31% Talenttop 38% Markettop 43% Growthtop 48% Newsbottom 42% Techbottom 38% Globalbottom 37% Funding: Raised $174M across 20 rounds · 20 rounds over 18 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 55/100 | $174M | 5 mo ago | Series E | 100 100 → 128 (+28%) | Richard Tyc Co-Founder & SVP Science & Technology | — | — | — |
| 3 | Endogenex Developer of medical devices for the treatment of Type 2 diabetes 37Funding top 18%Innovation top 39%Moat top 39%Patents top 41% All 9 signals ▾Fundingtop 18% Innovationtop 39% Moattop 39% Patentstop 41% Talentbottom 49% Globalbottom 37% Techbottom 35% Marketbottom 31% Newsbottom 20% Funding: Raised $140M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Innovation: 25 patents (top 67% of patent-holders) · 24 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $140M | 5 mo ago | Series C | 15 15 → 27 (+80%) | Michael Brenzel Co-Founder & CTO | WordPress Block EditorWordPressMySQL+16 | 25 patents Pulsed electric field tissue ablation devices for medical/clinical applications | — |
| 4 | Delphinus Medical Technologies Platform for breast ultrasound imaging | $114M | 29 mo ago | Series D | 48 | Neb Duric Co-Founder & Chief Technology Officer | ExpressionEngineApple iCloud MailSalesforce+23 | — | — |
| 5 | Entellus Medical Developer of suite of products for treating chronic sinusitis | $91M | 109 mo ago | Acquired | 286 | — | — | 253 patents Minimally invasive sinus endoscopy and balloon dilation catheter technologies for sinus treatment | — |
| 6 | ev3 Endovascular Surgical products for treatment of Peripheral vascular & Neurovascular diseases | $59M | 290 mo ago | Acquired | 1,307 | — | — | 80 patents Cardiovascular occlusion devices for septal and atrial defects | — |
| 7 | Atritech Latest women's fashion trends: flare skirts and tweed vests | $52M | 209 mo ago | Acquired | 27 | — | — | 103 patents Left atrial appendage blood filtration and implant delivery devices | — |
| 8 | Urotronic Developer of smart devices for treating urethral stricture | $47M | 70 mo ago | Acquired | 18 | — | WordPressMySQLPHP+16 | 93 patents Drug‑coated balloon catheters for delivering therapeutics to vascular and non‑vascular lumens | — |
| 9 | Celsee Diagnostics Provider of liquid biopsy technology to monitor circulating tumor cells (CTC) | $38M | 80 mo ago | Acquired | 18 | — | — | 55 patents Automated single-cell capture, isolation, and analysis platforms for diagnostic and research applications. | — |
| 10 | Reprise Biomedical Developer of surgical mesh for wound management | $23M | 3 mo ago | Series B | 16 | Carrie Powers Chief Executive Officer | WordPressApple iCloud MailMySQL+24 | — | — |
| 11 | Interrad Medical Innovative medical device company reducing catheter complications and improving patient outcomes | $21M | 141 mo ago | Series C | 17 17 → 27 (+59%) | — | — | 285 patents Secure anchoring solutions for IV cannulas, catheters, and implantable medical devices | — |
| 12 | Incisive Surgical Developer of absorbable skin stapler for surgical use | $13M | 202 mo ago | Series A | 17 | John Shannon CEO & President | WordPressSentryMySQL+29 | 43 patents Advanced surgical wound closure and bilateral tissue fastening devices | — |
| 13 | SpineThera Developer of injectable drugs for back pain | $12M | 52 mo ago | Acquired | 6 | Jeff Missling Founder & CEO | — | 27 patents Advanced pharmaceutical formulations for targeted drug delivery and composition optimization. | — |
| 14 | Silk Tech Innovating with silk-derived proteins for healthier, sustainable product development | $11M | 106 mo ago | Series A | 34 | Brian Lawrence Co-Founder & CEO | — | — | — |
| 15 | Tissue Regeneration Systems Pioneering skeletal reconstruction through tissue regeneration systems | $11M | 135 mo ago | Series A | 6 | — | — | — | — |
| 16 | Mardil Implantable therapies for structural heart diseases | $10M | 93 mo ago | Deadpooled | 11 | — | — | 109 patents Implantable cardiac support devices with self‑adjusting attachment mechanisms. | — |
| 17 | MetaModix Innovating metabolic disease treatments for Type 2 Diabetes, Obesity, and NASH | $6M | 98 mo ago | Series A | 4 | — | — | 112 patents Gastrointestinal implant anchoring and anti‑migration devices for prostheses and bypass sleeves | — |
| 18 | Advaita Bioinformatics Provider of bioinformatics software tools focused on multi-omics pathway analysis | $4M | 31 mo ago | Funding Raised | 7 | — | — | — | — |
| 19 | Peytant Solutions Developer of a regenerative medical device for the treatment of luminal diseases | $4M | 42 mo ago | Seed | — | John Schorgl Co-Founder | — | 10 patents Amnion tissue‑coated vascular stents and delivery devices for regenerative cardiovascular therapy | — |
| 20 | SILKTEARS Developer of protein-based eye drops | $4M | 32 mo ago | Series A | — | Jeff Poe CEO | — | 2 patents Silk protein-based ophthalmic drugs and oxidation-enabled silk fibroin surface coating technologies. | — |
| 21 | Biosavita Developer of yeast platform to produce antibodies against infectious diseases | $3M | 158 mo ago | Series A | — | Nalini Motwani Founder & President | — | — | — |
| 22 | TGS Knee Innovations Orthopedic implant system that kinematically restore knee function to arthritis patients | $2M | 183 mo ago | Deadpooled | — | Wesley D. Johnson CEO | — | — | — |
| 23 | SoftSeal Hemostatic pads for wound care | $2M | 52 mo ago | Seed | 6 | Michael Reilly President & CEO | — | — | — |
| 24 | Chitogen Hemostatic pads for wound care | $2M | 52 mo ago | Seed | — | Michael Reilly President & CEO | — | — | — |
| 25 | Hennepin Life Sciences Developer of drugs for the treatment of bacterial and yeast infections | $2M | 114 mo ago | Seed | 3 | Tom Burke CEO & Co-Founder | — | — | — |
| 26 | Uromedica Adjustable continence therapy solutions for stress urinary incontinence in men and women | $2M | 91 mo ago | Early Stage | 17 17 → 34 (+100%) | John Burton Co-Founder | WixSentryBootstrap+10 | 76 patents Implantable urinary continence devices with fixation anchors and monitoring systems | — |
| 27 | Subq IT Bioabsorbable skin closure system specially designed for closing small incisions | $300K | 34 mo ago | Seed | 3 | Chuck Rogers CEO | Cart FunctionalityWixSentry+12 | 3 patents Implantable biosensors for continuous physiological monitoring and data transmission | — |
| 28 | Novidan Innovating affordable, high-quality OTC hearing aids with advanced technology | $300K | 92 mo ago | Seed | 23 | Pete Salmi Founder and CEO | — | — | — |
| 29 | ActivOrtho Developer of implants for bone fixation | $300K | 55 mo ago | Seed | 2 | — | — | 29 patents Active orthopedic compression devices with torque monitoring for bone fixation | — |
| 30 | Ehmet Health Developer of radiotherapeutic devices for treating breast cancer | $150K | 70 mo ago | Seed | 6 | Michael Teicher CEO | — | — | — |
| 31 | Nonin Medical Noninvasive medical monitoring solutions | $148K | 135 mo ago | Funding Raised | 176 176 → 255 (+45%) | — | WordPressApple iCloud MailMicrosoft 365+33 | 169 patents Wearable photoplethysmography sensors for continuous pulse oximetry and respiration monitoring. | 1 job opening · 1 launch |
| 32 | ABS Ortho Graduate school offering education, research, and degree programs | $132K | 167 mo ago | Early Stage | — | Pete Jensen CEO | — | — | — |
Top 12 Life Sciences companies in Plymouth
#1
Series E · Plymouth, Minnesota · founded 1999 · 100 employees$174.3Mraised▾
Monteris Medical is focused on providing innovative MRI-guided neurosurgical ablation tools and solutions for neurosurgeons. By combining the imaging power of Magnetic Resonance Imaging (MRI), advanced navigation software and Laser Interstitial Thermal Therapy (LITT), Monteris Medical has created a system to reach virtually any area of the brain.
- Mar 2026Series E$28M
- Mar 2026Conventional Debt$35M
- Oct 2022Conventional Debt$38M
- Oct 2022Series D$35M
#2
Series C · Plymouth, Minnesota · founded 2017 · 15 employees$140.4Mraised▾
Developer of medical devices for the treatment of Type 2 diabetes. The company has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with Type 2 diabetes.
- Mar 2026Series C$50M
- Jun 2024Series C$88M
- Oct 2023Series B$18.3M
- Feb 2023Series A$9.2M
#3
Series B · Plymouth, Minnesota · founded 2019 · 16 employees$23.1Mraised▾
Developer of surgical mesh for wound management. The products developed are FDA-approved MIRODERM (derived from the porcine liver) and MIROMESH (non-crosslinked acellular surgical mesh) that uses perfusion decellularization technology. It is used to treat wounds, ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, tunneled and undermined wounds, trauma wounds, drainage wounds, and surgical wounds.
- Jun 2025Series B$6.4M
- Jan 2023Series B$15.3M
- Mar 2021Series A$5M
- Nov 2020Seed$2.8M
#4
Acquired · Plymouth, Minnesota · founded 2022 · 19 employees$242Mraised▾
Developer of precision combination therapies for cancer. It offers IDRX-42 and IDRX-73 small molecule tyrosine kinase inhibitors to inhibit the key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumors.
- Aug 2024Series B$120M
- Aug 2022Series A$122M
#5
Series D · Plymouth, Michigan · founded 2010 · 48 employees$114.2Mraised▾
Delphinus Medical Technologies has designed and developed SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women’s breasts for the presence of benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. Sound and water are the basis of its technology, where acoustic signals resonating within breast tissue yield a unique signature that it measures. SoftVue has received FDA clearance for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography.
- Mar 2024Series D$27.6M
- Aug 2023Venture Debt$12M
- Jun 2023Series D$5M
- Sep 2022Series D$30M
#6
Acquired · Plymouth, Michigan · founded 2006 · 286 employees$90.5Mraised▾
Entellus is developing products for the minimally invasive treatment of chronic sinusitis. The company has developed its XprESS family of products used to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.
- Jul 2017Post IPO$50M
- 2016Post IPO—
- Oct 2012Conventional Debt$17M
- Aug 2011Series E$35M
#7
Funding Raised · Plymouth, Michigan · founded 2005 · 7 employees$4.2Mraised▾
Provider of bioinformatics software tools focused on multi-omics pathway analysis. The company offers iPathwayGuide, is a next-generation pathway analysis platform that enables rapid and accurate interpretation of gene expression and other omics data.
- Jan 2024Grant (prize money)$1.7M
- Sep 2014Grant (prize money)$250K
- Aug 2011Grant (prize money)$2.2M
#8
Acquired · Plymouth, Minnesota · founded 2015 · 18 employees$47.1Mraised▾
Urotronic has developed a urethral medical device The product developed is the Optilume drug-coated balloon used for urethral stricture treatment. The proprietary technology combines balloon dilation and drug delivery technology. The uptake of the lipophilic drug, paclitaxel, helps in limiting hyperactive cell proliferation and the fibrotic scar tissue generation that causes stricture recurrence.
- Oct 2020Series C$20M
- Aug 2018Series B$20M
- Jul 2018Series A$6.1M
#9
Acquired · Plymouth, Michigan · founded 2011 · 18 employees$38.4Mraised▾
Provider of liquid biopsy technology to monitor circulating tumor cells (CTC). The company offers an instrument system and reagent kit that allows for the separation, detection, and retrieval of CTCs from peripheral whole blood as an alternative to traditionally painful and invasive biopsies. The company's product will allow researchers to identify, capture rare and difficult to harvest cancer cells in a microfluidic chip and also enable them to conduct a downstream molecular analysis.
- Dec 2019Series B$5.1M
- Nov 2018Series B$18.5M
- May 2018Conventional Debt$2.4M
- Oct 2017Series A$7.9M
#10
Acquired · Plymouth, Minnesota · founded 2012 · 6 employees$11.5Mraised▾
Developer of injectable drugs for back pain. The company's lead candidate utilizes patent-protected sustained-release drug-delivery technology which is an anti-inflammatory steroid to reduce frequent epidural injections for back pain.
- Apr 2022Grant (prize money)$5M
- Jun 2021Series A$1.2M
- Jun 2021Conventional Debt—
- Nov 2018Series A$2M
#11
Series A · Plymouth, Minnesota · founded 2022$3.6Mraised▾
Developer of protein-based eye drops. The company has developed an over-the-counter eye drop product called SilkTears to provide lasting eye relief and improve tear quality.
- Dec 2023Series A$3.6M
#12
Acquired · Plymouth, Minnesota · founded 2000 · 1307 employees$58.8Mraised▾
ev3 Endovascular (previously known as Vertomed) develops, manufactures, and commercializes equipment, technologies, and solutions for the treatment of peripheral vascular and neurovascular diseases. Its products include plaque excision systems, stents, carotid stents, percutaneous transluminal angioplasty balloons, embolic protection devices, thrombus management systems, blood clot therapy products, procedural support products, embolization coils, liquid embolics, micro catheters, thrombectomy catheters, occlusion balloons, guidewires, and retrieval devices. The company sells more than 100 products in more than 65 countries through a direct sales team and distributors. Among its customers are radiologists, cardiologists, neurosurgeons, and vascular surgeons. The company sells its products in Asia Pacific, Latin America, Eastern Europe, and the Middle East. eV3 endovascular was acquired by Covidien in 2010 for $2.6 Billion. Before beinmg acquired by Covidien, eV3 had acquired Endicor Medical, Microvena, Mitralife, Appriva Medical, Intratherapeutics.
- 2002Series A$58.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.